Epidermolysis Bullosa, also colloquially known as butterfly skin disease, a rare genetic condition that makes your skin very ...

Severe dystrophic epidermolysis bullosa is a rare genetic condition affecting 1 in every 500,000 people. Those with the disease have a defect in the gene for collagen VII, a protein that normally ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

It’s so special to be playing for a purpose, the purpose being this incredible mission,” Eddie Vedder tells TODAY.com.

The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a ...

A Mayo student with a rare, genetic skin disease hopes to raise €5,000 by abseiling from the roof of Croke Park to raise ...

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S.

The U.S. Food and Drug Administration (FDA) has approved prademagene zamikeracel (Zevaskyn) for the treatment of blistering ...

A courageous Mayo student living with a rare and painful genetic skin disease is preparing to abseil from the roof of Croke ...

Abeona Therapeutics' Zevaskyn, a cell therapy based on engineered keratinocytes harvested from patients, has been approved in ...

The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) for use in ...